Ephedrine
| Evidence Level: L4 | Predicted Indications: 3 |
Table of Contents
Ephedrine: From Cold, Flu and Cough Combination Products to Nasal Cavity Disease
One-Sentence Summary
Ephedrine is a sympathomimetic drug. In South Africa it is registered mainly in oral cold, flu and cough products, although the supplied record does not state an approved indication. The TxGNN model predicts it may be useful for nasal cavity disease. The evidence is thin: the trials listed are only loosely related, and none clearly tests ephedrine. 1 randomised study compares a related decongestant (pseudoephedrine), and the remaining publications are animal models or older reports.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the supplied registration data (inferred from product names: cold, flu and cough combinations) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 13 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not in the supplied record, so this reasoning rests on general pharmacology. Ephedrine is a mixed-acting sympathomimetic. It releases norepinephrine and directly stimulates alpha-adrenergic receptors. This constricts the blood vessels of the nasal lining and reduces swelling and congestion.
This is consistent with the long-standing use of ephedrine and pseudoephedrine as nasal decongestants. Nasal congestion is central to many nasal cavity diseases, so the prediction is biologically plausible.
The high TxGNN score is a model output only. It is not clinical proof. Systemic effects (raised blood pressure, fast heart rate, CNS stimulation) would also need review for any new use.
Clinical Trial Evidence
None of the trials below clearly tests ephedrine as the intervention. Most are linked to nasal cavity disease only by the condition.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00562120 | Phase 2 | Completed | 21 | Randomised, double-blind, placebo-controlled crossover study of an H3 antagonist (PF-03654746) on nasal congestion after allergen challenge. The design suits a decongestant study, but ephedrine’s involvement is unconfirmed. |
| NCT03620513 | Phase 4 | Completed | 160 | Topical anaesthesia vs decongestant vs both for comfort during fibreoptic nasal laryngoscopy. The decongestant used is not specified here. |
| NCT01886768 | N/A | Unknown | 212 | Single vs double pledget nasal anaesthesia and decongestion for transnasal endoscopy. |
| NCT06457100 | Phase 1/2 | Active, not recruiting | 60 | Esmolol vs lidocaine infusion in endoscopic sinus surgery. Epinephrine use is mentioned, but ephedrine is not tested. |
| NCT05494346 | N/A | Recruiting | 101 | Decongestant seawater spray (device) for acute rhinitis. No ephedrine. |
| NCT06580210 | N/A | Recruiting | 114 | Seawater decongestant spray, post-market study. No ephedrine. |
| NCT06010316 | N/A | Unknown | 200 | Cohort study of surgery for chronic rhinosinusitis. |
| NCT04645511 | N/A | Recruiting | 120 | Placebo-controlled balloon sinuplasty study in maxillary sinusitis (procedure trial). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11345158 | 2001 | RCT | Am J Rhinol | Compared oral and topical decongestant effects of phenylpropanolamine and d-pseudoephedrine, using acoustic rhinometry to measure nasal cavity dimensions. Ephedrine itself was not tested. |
| 14211229 | 1964 | Clinical study | Svenska Lakartidningen | Experimental clinical testing of a promethazine derivative combined with ephedrine hydrochloride in the nasal cavity. |
| 1541887 | 1992 | Comparative clinical study | J Laryngol Otol | Nasal packing vs spraying for pre-operative nasal preparation. |
| 12962193 | 2003 | Animal model | Am J Rhinol | Model of allergic nasal congestion in ragweed-sensitised dogs, measured by acoustic rhinometry. |
| 12387934 | 2002 | Animal model | J Pharmacol Toxicol Methods | Pharmacological characterisation of a dog model of nasal congestion for studying decongestant mechanisms. |
| 11895194 | 2002 | Animal model | Am J Rhinol | Acoustic rhinometry in dogs as a large-animal model for nasal congestion. |
| 11789239 | 2000 | Clinical observation | Zhongguo Zhong Xi Yi Jie He Za Zhi | Preliminary observation of a rhinitis spray in chronic rhinitis. |
South Africa Market Information
There are 13 registrations in total; five are shown. Dosage forms across all registrations are syrup, tablet and capsule. Approved indication text is not stated in the supplied record.
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| C795 (OM) | Grippon Cold And Flu Syrup | Syrup | Not stated |
| G1236 | Codef Cough | Syrup | Not stated |
| 29/5.8/0782 | Sinuend | Tablet | Not stated |
| G979 | Sinucon | Tablet | Not stated |
| C 810 (OM) | Colcleer (cold + flu) | Tablet | Not stated |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Ephedrine’s sympathomimetic effects (hypertension, tachycardia, CNS stimulation) warrant a formal safety review before any new use. This is general pharmacology, not registration-specific data. No drug interaction records were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanism is plausible, but no trial in the pack clearly tests ephedrine for nasal cavity disease. The strongest human evidence is one RCT of a related drug (pseudoephedrine). The SAHPRA safety data is missing, which blocks safety screening. This is currently a research question, not a candidate for action.
The two lower-ranked predictions (acute laryngopharyngitis, 99.90%; trigeminal autonomic cephalalgia, 99.34%) have no trials or literature. For trigeminal autonomic cephalalgia, ephedrine’s stimulant effects could plausibly worsen headache, so it should not be pursued on current evidence.
To proceed, the following is needed:
- SAHPRA package insert warnings and contraindications (download and parse the PI PDF), which is the blocking gap
- Mechanism of action data from DrugBank
- Approved indication text for the 13 SAHPRA registrations
- Verification of whether ephedrine is an arm in NCT00562120 and NCT03620513
- Ephedrine-specific clinical evidence in nasal congestion or nasal cavity disease
- A cardiovascular and CNS safety review for the intended population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.